D. Boral Capital Reaffirms Buy Rating for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "buy" rating reissued by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price target on the medical research company's stock.

A number of other equities research analysts have also recently issued reports on CTSO. HC Wainwright restated a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a report on Thursday, May 15th. Wall Street Zen assumed coverage on shares of Cytosorbents in a research report on Wednesday, May 21st. They set a "hold" rating for the company.

Cytosorbents Stock Up 0.5%

Shares of NASDAQ CTSO traded up $0.01 during mid-day trading on Monday, hitting $1.04. The company had a trading volume of 21,288 shares, compared to its average volume of 145,295. The company has a market capitalization of $64.80 million, a PE ratio of -3.75 and a beta of 1.19. The firm has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.03. The company has a current ratio of 2.61, a quick ratio of 2.30 and a debt-to-equity ratio of 0.98. Cytosorbents has a one year low of $0.71 and a one year high of $1.61.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.01 million. Cytosorbents had a negative return on equity of 105.04% and a negative net margin of 41.77%. On average, equities analysts expect that Cytosorbents will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC grew its position in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after acquiring an additional 8,400 shares in the last quarter. Northern Trust Corp raised its stake in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after acquiring an additional 16,701 shares during the last quarter. Millennium Management LLC bought a new position in shares of Cytosorbents during the fourth quarter valued at about $30,000. Goldman Sachs Group Inc. increased its position in shares of Cytosorbents by 149.2% during the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company's stock valued at $63,000 after buying an additional 37,519 shares during the period. Finally, Key Client Fiduciary Advisors LLC increased its position in shares of Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock valued at $78,000 after buying an additional 43,900 shares during the period. Institutional investors own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.